Sanofi-Aventis pulls out of TroVax but in ocular deal with Oxford BioMedica

Sanofi-Aventis has pulled out of developing Oxford BioMedica's novel cancer vaccine TroVax, but will pay the UK company £34 million to develop four preclinical ocular therapies.